Aktis Oncology Raises $365.4M IPO, Launches Phase 1b AKY-2519 Trial in mCRPC
Aktis Oncology completed a $365.4 million IPO in January and initiated a Phase 1b trial of AKY-2519 in mCRPC following FDA IND clearance, with preliminary data expected in 2027. It also enrolled patients in the Phase 1b AKY-1189 Nectin-4 program, receiving Fast Track status and targeting data in Q1 2027.
1. Q1 2026 Financial Highlights
Aktis Oncology closed an initial public offering of 20.3 million shares at $18.00 per share in January, generating gross proceeds of approximately $365.4 million. The capital raise strengthens the balance sheet to fund ongoing and planned clinical programs throughout 2026 and beyond.
2. AKY-2519 Phase 1b Trial
Following FDA clearance of its INDs, the company launched a multicenter Phase 1b trial of AKY-2519 in PLUVICTO-naïve and PLUVICTO-experienced metastatic castration-resistant prostate cancer patients. A second Phase 1b basket trial in B7-H3 expressing solid tumors is slated to start in H2 2026, with clinical imaging and dosimetry data presented at ASCO 2026.
3. AKY-1189 Fast Track and Enrollment
AKY-1189 received Fast Track designation for adult patients with advanced or metastatic urothelial cancer and is enrolling in its ongoing Phase 1b trial across mUC, breast, lung, colorectal, cervical and head and neck tumors. The company anticipates reporting preliminary safety and efficacy data in the first quarter of 2027.
4. Upcoming Pipeline and Corporate Milestones
Two early-stage programs are on track for development candidate nominations and IND-enabling activities by Q1 2027, while an in-house GMP facility is expected to be operational later this year. Management also appointed Glenn Gormley, MD, PhD to co-chair its new Science and Technology Committee.